

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7203942/publications.pdf>

Version: 2024-02-01

40
papers

4,394
citations

361296

20
h-index

265120

42
g-index

49
all docs

49
docs citations

49
times ranked

7870
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment related factors associated with the risk of breast radio-induced-sarcoma. <i>Radiotherapy and Oncology</i> , 2022, 171, 14-21.	0.3	6
2	Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study. <i>Tumori</i> , 2022, , 030089162210780.	0.6	3
3	Proof of Concept of a Binary Blood Assay for Predicting Radiosensitivity. <i>Cancers</i> , 2021, 13, 2477.	1.7	9
4	Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood. <i>BMC Immunology</i> , 2021, 22, 38.	0.9	7
5	Impact of proton therapy on antitumor immune response. <i>Scientific Reports</i> , 2021, 11, 13444.	1.6	27
6	Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. , 2021, 9, e002256.		18
7	Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies. <i>Cancers</i> , 2021, 13, 4893.	1.7	19
8	About the Influence of PEG Spacers on the Cytotoxicity of Titanate Nanotubes-Docetaxel Nanohybrids against a Prostate Cancer Cell Line. <i>Nanomaterials</i> , 2021, 11, 2733.	1.9	1
9	Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer. <i>Cells</i> , 2020, 9, 2071.	1.8	10
10	In-vivo and in-vitro impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response. <i>Clinical and Translational Radiation Oncology</i> , 2020, 24, 116-122.	0.9	7
11	Polydopamine Modified Superparamagnetic Iron Oxide Nanoparticles as Multifunctional Nanocarrier for Targeted Prostate Cancer Treatment. <i>Nanomaterials</i> , 2019, 9, 138.	1.9	47
12	The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response. <i>Cancers</i> , 2019, 11, 860.	1.7	75
13	Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. , 2019, 7, 160.		132
14	RILA blood biomarker as a predictor of radiation-induced sarcoma in a matched cohort study. <i>EBioMedicine</i> , 2019, 41, 420-426.	2.7	12
15	Titanate Nanotubes Engineered with Gold Nanoparticles and Docetaxel to Enhance Radiotherapy on Xenografted Prostate Tumors. <i>Cancers</i> , 2019, 11, 1962.	1.7	22
16	HSP110 translocates to the nucleus upon genotoxic chemotherapy and promotes DNA repair in colorectal cancer cells. <i>Oncogene</i> , 2019, 38, 2767-2777.	2.6	26
17	Clinical and dosimetric study of radiotherapy for glioblastoma: three-dimensional conformal radiotherapy versus intensity-modulated radiotherapy. <i>Journal of Neuro-Oncology</i> , 2018, 137, 429-438.	1.4	18
18	Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study. <i>OncImmunology</i> , 2018, 7, e1396402.	2.1	29

#	ARTICLE	IF	CITATIONS
19	Taxaneâ€Grafted Metalâ€Oxide Nanoparticles as a New Theranostic Tool against Cancer: The Promising Example of Docetaxelâ€Functionalized Titanate Nanotubes on Prostate Tumors. <i>Advanced Healthcare Materials</i> , 2017, 6, 1700245.	3.9	20
20	NOX2-dependent ATM kinase activation dictates pro-inflammatory macrophage phenotype and improves effectiveness to radiation therapy. <i>Cell Death and Differentiation</i> , 2017, 24, 1632-1644.	5.0	50
21	Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 6357-6364.	3.3	18
22	Absolute volume of the rectum and AUC from rectal DVH between 25Gy and 50Gy predict acute gastrointestinal toxicity with IG-IMRT in prostate cancer. <i>Radiation Oncology</i> , 2016, 11, 145.	1.2	8
23	Correlation between radio-induced lymphocyte apoptosis measurements obtained from two French centres. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2016, 20, 391-394.	0.6	8
24	A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2016, 20, 193-198.	0.6	8
25	The role of telomeres in predicting individual radiosensitivity of patients with cancer in the era of personalized radiotherapy. <i>Cancer Treatment Reviews</i> , 2015, 41, 354-360.	3.4	20
26	207 The enhancement of radiotherapy efficacy with docetaxel-titanate nanotubes as a new nanohybrid for localized high risk prostate cancer. <i>European Journal of Cancer</i> , 2014, 50, 67.	1.3	3
27	The radiosensitization effect of titanate nanotubes as a new tool in radiation therapy for glioblastoma: A proof-of-concept. <i>Radiotherapy and Oncology</i> , 2013, 108, 136-142.	0.3	87
28	Survivin-3B Potentiates Immune Escape in Cancer but Also Inhibits the Toxicity of Cancer Chemotherapy. <i>Cancer Research</i> , 2013, 73, 5391-5401.	0.4	23
29	Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer. <i>Radiotherapy and Oncology</i> , 2012, 103, 244-246.	0.3	49
30	Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups. <i>Radiation Oncology</i> , 2012, 7, 158.	1.2	6
31	Early Choline Levels From 3-Tesla MR Spectroscopy After Exclusive Radiation Therapy in Patients With Clinically Localized Prostate Cancer are Predictive of Plasmatic Levels of PSA at 1 Year. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e407-e413.	0.4	8
32	Tumor Volume and Metabolism of Prostate Cancer Determined by Proton Magnetic Resonance Spectroscopic Imaging at 3T Without Endorectal Coil Reveal Potential Clinical Implications in the Context of Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1087-1094.	0.4	22
33	Anti-Cancer Therapeutic Approaches Based on Intracellular and Extracellular Heat Shock Proteins. <i>Current Medicinal Chemistry</i> , 2007, 14, 2839-2847.	1.2	126
34	Apoptosis Versus Cell Differentiation. <i>Prion</i> , 2007, 1, 53-60.	0.9	205
35	HSP27 favors ubiquitination and proteasomal degradation of p27 Kip1 and helps Sâ€phase reâ€entry in stressed cells. <i>FASEB Journal</i> , 2006, 20, 1179-1181.	0.2	95
36	NF-â€B modulation and ionizing radiation: mechanisms and future directions for cancer treatment. <i>Cancer Letters</i> , 2006, 231, 158-168.	3.2	166

#	ARTICLE	IF	CITATIONS
37	The Polycomb group protein EZH2 directly controls DNA methylation. <i>Nature</i> , 2006, 439, 871-874.	13.7	1,964
38	Heat Shock Proteins 27 and 70: Anti-Apoptotic Proteins with Tumorigenic Properties. <i>Cell Cycle</i> , 2006, 5, 2592-2601.	1.3	615
39	Myc represses transcription through recruitment of DNA methyltransferase corepressor. <i>EMBO Journal</i> , 2005, 24, 336-346.	3.5	375
40	Arachidonic acid activates a functional AP-1 and an inactive NF- κ B complex in human HepG2 hepatoma cells. <i>Free Radical Biology and Medicine</i> , 2003, 35, 636-647.	1.3	25